Component

N-acetyl-S-allyl-L-cysteine

Context-specific entity; species, compartment and exposure are stated on each claim.

4 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. N-acetyl-SAC decomposed in the detector source and interfered with SAC quantification unless chromatographic separation was used.

    N-acetyl-S-allyl-L-cysteine → SAC/NAc-SAC mass-spectrometric source interference source_derived_draftungraded
    Experimental context and source evidence
    acting_entity
    n-acetyl-s-allylcysteine
    dose
    Calibration and source-fragmentation experiment
    duration
    Analytical assay
    evidence_access
    Primary abstract
    experimental_comparison
    SAC and metabolite standards with chromatographic separation
    experimental_model
    LC-MS/MS assay validation
    interpretation_status
    Source-derived research curation; not independent primary verification
    limitations
    Analytical artifact, not biological conversion or an increase in in-vivo SAC.
    nutrient_topic
    S-allylcysteine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · S-allyl-L-cysteine / SAC
    organism
    Rat plasma analytical matrix
    plain_language
    A metabolite can make an analytical SAC signal misleading.
    primary_references
    [28561204] Oral Administration of (S)-Allyl-l-Cysteine and Aged Garlic Extract to Rats: Determination of Metabolites and Their Pharmacokinetics. · 2017 · https://pubmed.ncbi.nlm.nih.gov/28561204/ · DOI 10.1055/s-0043-111895
    route
    Ex vivo
    tissue_or_cell_type
    LC-MS/MS assay validation

    S-allylcysteine: sulfur signaling, redox responses and cross-nutrient mechanisms (2026-09-20) · lines 50–57

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · LC-MS/MS assay validation · source_derived_draft · unverified_draft

    ## s-allylcysteine-analytical-interference A metabolite can make an analytical SAC signal misleading. N-acetyl-SAC decomposed in the detector source and interfered with SAC quantification unless chromatographic separation was used. Model: LC-MS/MS assay validation Limitations: Analytical artifact, not biological conversion or an increase in in-vivo SAC. Evidence access: Primary abstract [28561204] Oral Administration of (S)-Allyl-l-Cysteine and Aged Garlic Extract to Rats: Determination of Metabolites and Their Pharmacokinetics. · 2017 · https://pubmed.ncbi.nlm.nih.gov/28561204/ · DOI 10.1055/s-0043-111895 Structured context: {"organism": "Rat plasma analytical matrix", "tissue_or_cell_type": "LC-MS/MS assay validation", "dose": "Calibration and source-fragmentation experiment", "duration": "Analytical assay", "route": "Ex vivo", "experimental_comparison": "SAC and metabolite standards with chromatographic separation", "acting_entity": "n-acetyl-s-allylcysteine", "interpretation_status": "Source-derived research curation; not independent primary verification"}
    Complete structured claim and evidence

  2. The same S9 preparations deacetylated N-acetyl-SAC; SAC also appeared in plasma after intravenous N-acetyl-SAC.

    N-acetyl-S-allyl-L-cysteine → S-allyl-L-cysteine / SAC source_derived_draftungraded
    Experimental context and source evidence
    acting_entity
    n-acetyl-s-allylcysteine
    dose
    Rats 5 mg/kg; dogs 2 mg/kg
    duration
    Single administration
    evidence_access
    Primary abstract
    experimental_comparison
    Purified SAC or N-acetyl-SAC; corresponding pharmacokinetic comparisons
    experimental_model
    Oral/i.v. pharmacokinetics; liver and kidney S9 experiments
    interpretation_status
    Source-derived research curation; not independent primary verification
    limitations
    Rat/dog finding, not a quantified human recycling rate.
    nutrient_topic
    S-allylcysteine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · S-allyl-L-cysteine / SAC
    organism
    Rat and dog
    plain_language
    The measured conversion could run back toward SAC.
    primary_references
    [25681129] Metabolism, excretion, and pharmacokinetics of S-allyl-L-cysteine in rats and dogs. · 2015 · https://pubmed.ncbi.nlm.nih.gov/25681129/ · DOI 10.1124/dmd.115.063230
    route
    Oral or intravenous; S9 incubation separately
    tissue_or_cell_type
    Oral/i.v. pharmacokinetics; liver and kidney S9 experiments

    S-allylcysteine: sulfur signaling, redox responses and cross-nutrient mechanisms (2026-09-20) · lines 23–30

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Oral/i.v. pharmacokinetics; liver and kidney S9 experiments · source_derived_draft · unverified_draft

    ## s-allylcysteine-deacetylation The measured conversion could run back toward SAC. The same S9 preparations deacetylated N-acetyl-SAC; SAC also appeared in plasma after intravenous N-acetyl-SAC. Model: Oral/i.v. pharmacokinetics; liver and kidney S9 experiments Limitations: Rat/dog finding, not a quantified human recycling rate. Evidence access: Primary abstract [25681129] Metabolism, excretion, and pharmacokinetics of S-allyl-L-cysteine in rats and dogs. · 2015 · https://pubmed.ncbi.nlm.nih.gov/25681129/ · DOI 10.1124/dmd.115.063230 Structured context: {"organism": "Rat and dog", "tissue_or_cell_type": "Oral/i.v. pharmacokinetics; liver and kidney S9 experiments", "dose": "Rats 5 mg/kg; dogs 2 mg/kg", "duration": "Single administration", "route": "Oral or intravenous; S9 incubation separately", "experimental_comparison": "Purified SAC or N-acetyl-SAC; corresponding pharmacokinetic comparisons", "acting_entity": "n-acetyl-s-allylcysteine", "interpretation_status": "Source-derived research curation; not independent primary verification"}
    Complete structured claim and evidence

  3. N-acetyl-SAC inhibited the CYP2D6 probe reaction by 19% at 1 mM.

    N-acetyl-S-allyl-L-cysteine → Human cytochrome P450 2D6 source_derived_draftungraded
    Experimental context and source evidence
    acting_entity
    n-acetyl-s-allylcysteine
    dose
    SAC 0.01–1 mM; N-acetyl-SAC 1 mM
    duration
    Probe-specific incubation
    evidence_access
    Primary full-text HTML, abstract/results
    experimental_comparison
    Test compound versus probe reaction without compound
    experimental_model
    Pooled human liver microsomes; probe substrate metabolism
    interpretation_status
    Source-derived research curation; not independent primary verification
    limitations
    Small in-vitro effect; no patient interaction magnitude.
    nutrient_topic
    S-allylcysteine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · S-allyl-L-cysteine / SAC
    organism
    Human liver preparation
    plain_language
    A metabolite differed from the parent.
    primary_references
    [27725449] Evaluation of the Effects of S-Allyl-L-cysteine, S-Methyl-L-cysteine, trans-S-1-Propenyl-L-cysteine, and Their N-Acetylated and S-Oxidized Metabolites on Human CYP Activities. · 2016 · https://pubmed.ncbi.nlm.nih.gov/27725449/ · DOI 10.1248/bpb.b16-00449
    route
    In vitro
    tissue_or_cell_type
    Pooled human liver microsomes; probe substrate metabolism

    S-allylcysteine: sulfur signaling, redox responses and cross-nutrient mechanisms (2026-09-20) · lines 428–435

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Pooled human liver microsomes; probe substrate metabolism · source_derived_draft · unverified_draft

    ## s-allylcysteine-nac-cyp2d6 A metabolite differed from the parent. N-acetyl-SAC inhibited the CYP2D6 probe reaction by 19% at 1 mM. Model: Pooled human liver microsomes; probe substrate metabolism Limitations: Small in-vitro effect; no patient interaction magnitude. Evidence access: Primary full-text HTML, abstract/results [27725449] Evaluation of the Effects of S-Allyl-L-cysteine, S-Methyl-L-cysteine, trans-S-1-Propenyl-L-cysteine, and Their N-Acetylated and S-Oxidized Metabolites on Human CYP Activities. · 2016 · https://pubmed.ncbi.nlm.nih.gov/27725449/ · DOI 10.1248/bpb.b16-00449 Structured context: {"organism": "Human liver preparation", "tissue_or_cell_type": "Pooled human liver microsomes; probe substrate metabolism", "dose": "SAC 0.01–1 mM; N-acetyl-SAC 1 mM", "duration": "Probe-specific incubation", "route": "In vitro", "experimental_comparison": "Test compound versus probe reaction without compound", "acting_entity": "n-acetyl-s-allylcysteine", "interpretation_status": "Source-derived research curation; not independent primary verification"}
    Complete structured claim and evidence

What acts on it

  1. Rat and dog liver/kidney S9 fractions converted SAC to N-acetyl-SAC.

    S-allyl-L-cysteine / SAC → N-acetyl-S-allyl-L-cysteine source_derived_draftungraded
    Experimental context and source evidence
    acting_entity
    s-allylcysteine
    dose
    Rats 5 mg/kg; dogs 2 mg/kg
    duration
    Single administration
    evidence_access
    Primary abstract
    experimental_comparison
    Purified SAC or N-acetyl-SAC; corresponding pharmacokinetic comparisons
    experimental_model
    Oral/i.v. pharmacokinetics; liver and kidney S9 experiments
    interpretation_status
    Source-derived research curation; not independent primary verification
    limitations
    The specific acetyltransferase was not identified in the accessed abstract; do not assign a human enzyme.
    nutrient_topic
    S-allylcysteine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · S-allyl-L-cysteine / SAC
    organism
    Rat and dog
    plain_language
    Liver and kidney preparations modified the parent compound.
    primary_references
    [25681129] Metabolism, excretion, and pharmacokinetics of S-allyl-L-cysteine in rats and dogs. · 2015 · https://pubmed.ncbi.nlm.nih.gov/25681129/ · DOI 10.1124/dmd.115.063230
    route
    Oral or intravenous; S9 incubation separately
    tissue_or_cell_type
    Oral/i.v. pharmacokinetics; liver and kidney S9 experiments

    S-allylcysteine: sulfur signaling, redox responses and cross-nutrient mechanisms (2026-09-20) · lines 14–21

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Oral/i.v. pharmacokinetics; liver and kidney S9 experiments · source_derived_draft · unverified_draft

    ## s-allylcysteine-n-acetylation Liver and kidney preparations modified the parent compound. Rat and dog liver/kidney S9 fractions converted SAC to N-acetyl-SAC. Model: Oral/i.v. pharmacokinetics; liver and kidney S9 experiments Limitations: The specific acetyltransferase was not identified in the accessed abstract; do not assign a human enzyme. Evidence access: Primary abstract [25681129] Metabolism, excretion, and pharmacokinetics of S-allyl-L-cysteine in rats and dogs. · 2015 · https://pubmed.ncbi.nlm.nih.gov/25681129/ · DOI 10.1124/dmd.115.063230 Structured context: {"organism": "Rat and dog", "tissue_or_cell_type": "Oral/i.v. pharmacokinetics; liver and kidney S9 experiments", "dose": "Rats 5 mg/kg; dogs 2 mg/kg", "duration": "Single administration", "route": "Oral or intravenous; S9 incubation separately", "experimental_comparison": "Purified SAC or N-acetyl-SAC; corresponding pharmacokinetic comparisons", "acting_entity": "s-allylcysteine", "interpretation_status": "Source-derived research curation; not independent primary verification"}
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards